Suitable for which patients?

Inclusion Criteria (Partial)

Subjects must meet all of the following criteria to be enrolled in this study:

1) Subjects aged 18-75 years;

2) Advanced recurrent or metastatic solid tumors diagnosed by histology or cytology;

3) Disease progression occurs after standard treatment (radiological assessment), or intolerance to the standard treatment regimen, or the subject refuses other treatment options, or the investigator judges that other treatment options are expected to be less beneficial;

4) At least one resectable tumor lesion with a diameter of approximately 10mm, preferably collected through minimally invasive surgery for cell preparation.

Exclusion Criteria (Partial)

Subjects must also exclude all the following criteria that make them unsuitable for participating in this clinical study before they can be enrolled:

1) Those who have undergone organ transplantation or prior cell transplantation;

2) Subjects with a known history of hypersensitivity to any component of the study drug:

① Lymphocyte-depleting preconditioning drugs and IL-2;

② Aminoglycoside antibiotics (i.e., gentamicin), excluding patients with negative gentamicin hypersensitivity skin tests;

③Any component of the BEN201 Injection infusion product formulation, including dimethyl sulfoxide (DMSO) and human serum albumin (HSA).

3) Active central nervous system (CNS) metastases (excluding stable brain metastases that have not required medication for 3 months and are not hormone-dependent).

Clinical Benefit to Patients

1）Free Medication: The study drug will be provided free of charge until disease progression.

2）Free Examination: Free relevant tests required for the trial after being informed.

3）Transportation Allowance: Traffic subsidies related to clinical research.

4）Regular Follow-up by Experts: Full-service expert team, institutions focus on patients' physical conditions over the long term.

Project Implementation Region

The research is currently being conducted in areas such as Shanghai, and specific details will be confirmed through later consultation.

Summary of Required Documents to be Submitted

The materials that patients need to prepare and submit include:Pathology Report, Gene Test Report, Admission Record, Discharge Summary, CT/MRI Examination, Complete Blood Count, Liver and Kidney Function, Coagulation Function, Infectious Disease Screening, Electrocardiogram Reportetc.

Global Oncology Department Kindly Reminder

If you would like to participate in this clinical study or want to learn more about BEN201 injection, please contactGlobal Cancer Doctors Network Medical Department (400-666-7998), obtain more information about applications both in China and abroad, or apply directly. We commit to keeping all participants' personal information confidential and guarantee adherence to national laws and regulations related to clinical research throughout the process.